Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
James Janetka
Washington University, Department: Biochemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Fimbrion Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Based on WU’s Research COI Policy and the Procedures for Determining and Managing Research Financial Conflicts of Interests, the Conflicts of Interest Review Committee (CIRC) determined Dr. Janetka’s personal financial relationship with Fimbrion, related to the above referenced research, creates a financial conflict of interest due to the following reasons:
• The primary focus of Fimbrion Therapeutics, an entity with which he owns equity, is to commercialize the IP being evaluated in the above mentioned research.
• His personal financial relationship is directly related to the study because the study is evaluating a product licensed by Fimbrion.
• His role as principal investigator, as described below, could directly affect all aspects of the study.
While the CIRC determined Dr. Janetka has a financial conflict of interest, there are mitigating factors that help address the situation:
• Due to the research being basic in nature and in its early stages, the outcomes of the research are unlikely to directly impact the value of the company.
• Dr. Janetka is uniquely qualified by virtue of his expertise and experience, and the research could not be conducted as effectively without his involvement.
• Further research will be required to develop the IP into a commercialized product.
• Additionally, a plan has been developed to mitigate Dr. Janetka’s financial conflict of interest.
SMALL MOLECULE BACTERIAL LECTIN ANTAGONISTS FOR UTI TREATMENT AND PREVENTION
We will integrate reiterative X-ray structure-based drug design and synthetic medicinal chemistry with testing in a panel of biochemical and cellular assays followed by evaluation for pharmacokinetics and efficacy in animal models of urinary tract infections, to develop Gal- and GalNAc-based antagonists of the UPEC adhesin FmlH, which is used by uropathogenic E. coli (UPEC) to bind to the inflamed bladder tissue during chronic cystitis. Mannosides, inhibitors of FimH, an adhesin critical in acute and chronic infections, are efficacious in reducing UPEC bladder colonization. Thus, antagonists against FmlH will be tested either alone or together with high affinity mannosides in combination or as dual activity compounds. The goal is to identify new bioavailable small molecules as preclinical therapeutics for acute and chronic cystitis (bladder infection).
Filed on February 14, 2017.
Tell us what you know about James Janetka's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
James Janetka filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| James Janetka | Washington University | Conflict of Interest | Fimbrion Therapeutics | $0 - $4,999 |
| James Janetka | Washington University | Conflict of Interest | Fimbrion Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.